Kimberly-Clark has placed an ambitious bet on a troubled counterpart, agreeing to buy out Johnson & Johnson’s consumer health spinout Kenvue for $48.7 billion. More: Kimberly-Clark buys out Kenvue in .7B consumer health merger Source: fierce
read moreNeurology-focused patient groups’ perception of the pharma industry’s corporate reputation remains on a downward slope. More: Pharma’s corporate reputation dips among neurology patient groups, citing drug access challenges Source: fierce
read moreAfter Roche’s Gazyva won an FDA approval in lupus-related kidney disease, a phase 3 study now shows the med’s worth in systemic lupus erythematosus, the most common type of lupus. More: Roche's Gazyva, on an autoimmune hot streak, looks to
read more
Deal strengthens CNS portfolio and ensures continuity of access for MS patients More: CNX Therapeutics acquires Sativex from Jazz Pharmaceuticals Source: News
read more
Three-year trial results reveal long-term improvements in pain and lesion resolution More: bimekizumab data shows sustained benefits in hidradenitis suppurativa Source: News
read moreHigh-ranking FDA official George Tidmarsh, M.D., has tendered his resignation after an unconventional LinkedIn diatribe landed the senior drug regulator at the center of a lawsuit and an internal probe. More: CDER chief George Tidmarsh resigns as deleted LinkedIn post
read more© 1994 - 2025 B.M. Pharmaceuticals